Kivo reports that the Biotech Investment National Security Act of 2026 will expand U.S. licensing deal reviews to include biotechnology, creating new documentation requirements.
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you are a current print subscriber, you can set up a free website account by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
